[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:secondary-central-nervous-system-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":47,"states":48},"Secondary Central Nervous System Lymphoma",6,[7,15,22,28,35,41],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07137494","A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)",[11],"Phase 1","RECRUITING","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.527499Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05351593","Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma",[19],"Phase 1\u002FPhase 2","2026-08-26T02:15:33.331531Z","2026-07-19T19:36:05.117507Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT05256641","Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma",[19],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:28.530741Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT05681195","Zanubrutinib With Pemetrexed to Treat Relapsed\u002FRefractory Primary and Secondary Central Nervous System (CNS) Lymphomas",[32],"Phase 2","2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.471359Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[32],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[11],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:26.916657Z",[],[49,53,57],{"state":50,"count":51,"slug":52},"California",4,"california",{"state":54,"count":55,"slug":56},"Florida",3,"florida",{"state":58,"count":55,"slug":59},"New York","new-york"]